279results about "Filtration" patented technology

Blood treatment system and method for high rate hemofiltration ensures against pyrogenic patient reaction by providing various mechanisms for filtering replacement fluid to remove endotoxins and other safety features including detecting incorrect fluid administration.

The present invention relates to methods of making a sterilized biosensor, where the biosensor comprises at least one binding reagent, which comprises at least one non-enzyme proteinaceous binding domain. Certain embodiments of the methods described herein comprise partially assembling the components of the biosensor, except for the binding reagent, and separately sterilizing this partial assemblage and the binding reagent. The sterilized binding reagent and the sterilized partial assemblage are then aseptically assembled to produce the sterilized biosensor. Other embodiments of the methods described herein comprise assembling substantially all of the components of the biosensor, including the binding reagent, and sterilizing the assembled biosensor to produce a sterilized biosensor.

The invention is directed to a microbiological interception enhanced filter medium, preferably having an adsorbent prefilter located upstream from the filter medium. Preferably, the prefilter is adapted to remove natural organic matter in an influent prior to the influent contacting the microbiological interception enhanced filter medium, thereby preventing loss of charge on the filter medium. The microbiological interception enhanced filter medium is most preferably comprised of fibrillated cellulose fibers, in particular, lyocell fibers. At least a portion of the surface of the at least some of the fibers have formed thereon a microbiological interception enhancing agent comprising a cationic metal complex. A filter medium of the present invention provides greater than about 4 log viral interception, and greater than about 6 log bacterial interception.

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator / filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

The invention is directed to a microbiological interception enhanced filter medium, preferably having an adsorbent prefilter located upstream from the filter medium. Preferably, the prefilter is adapted to remove natural organic matter in an influent prior to the influent contacting the microbiological interception enhanced filter medium, thereby preventing loss of charge on the filter medium. The microbiological interception enhanced filter medium is most preferably comprised of fibrillated cellulose fibers, in particular, lyocell fibers. At least a portion of the surface of the at least some of the fibers have formed thereon a microbiological interception enhancing agent comprising a cationic metal complex. A filter medium of the present invention provides greater than about 4 log viral interception, and greater than about 6 log bacterial interception.

The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Accordingly, the present invention provides a method for reducing viral load in an individual comprising the steps of obtaining blood or plasma from the individual, passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are immobilized within the porous exterior portion of the membrane, collecting pass-through blood or plasma and reinfusing the pass-through blood or plasma into the individual.

The present invention provides a hydrophilic charged microporous membrane comprising a porous hydrophobic substrate and a coating comprising a charge-providing agent. The present invention further provides a hydrophilic charged membrane comprising a porous hydrophobic substrate and a hydrophilic charge-providing agent distributed within the substrate. The present invention further provides a filter as well as a filter device comprising the inventive hydrophilic charged membrane. The present invention further provides a process for treating a fluid containing bacterial contaminants such as endotoxins comprising contacting the membrane with the fluid to provide a bacterial contaminant depleted fluid.

A validatable method for determining a photochemically effective dose for inactivating pathogens in a fluid sample is described herein. In particular, the instant invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample while leaving biologically active substances of interest unaffected. A batch irradiation reactor effective for inactivating pathogens in biological samples is also described.

A vacuum cleaner attachment and method of use thereof provides an effective cleaning system for fungi and the like. A vacuum paddle extension enables the attachment to travel into narrow cracks and crevices where fungus may grow and by use of an abrasive and porous pad dislodges such fungus or fungi. When attached to a vacuum system, such as a HEPA (High Efficiency Particulate Air-Filtered) vacuum system, the debris and particulate matter generated by the abrasive process is drawn into the vacuum attachment and into the vacuum system where it is removed from the air which is then expelled by the vacuum system. Better cleaning of surfaces afflicted with fungi, molds, and the like is then achieved in a manner that is safer and more effective.

A reprocessor having a circulation system for circulating a microbial deactivation fluid through a chamber that forms a part of the circulation system. The reprocessor includes a water filtration system for filtering water used in the reprocessor. The water filtration system includes a fluid feed line connectable to a source of pressurized water. A first filter and second filter elements are disposed in the fluid feed line for filtering fluids flowing therethrough. The second filter element is downstream from the first filter element and has the capacity to filter particles smaller than the first filter element. The fluid feed line forms a fluid path for water entering the reprocessor, and defines a portion of a path for microbial deactivation fluid circulated through the circulation system.

The present invention relates, in general, to methods for removing viral contaminants from therapeutic protein solutions to improve safety of therapeutic proteins administered to patients. Particularly contemplated is the removal of small non-enveloped viruses, such as parvovirus, from therapeutic protein solutions.

A porous electrospun polymeric nanofiber liquid filtration medium, such as an electrospun mats, used for the removal of viral particles (e.g., parvovirus) and other particles in the 18 nm to 30 nm size range from fluid streams, having a mean flow bubble point measured with perfluorohexane above 100 psi. The electrospun medium includes nanofibers having an average fiber diameter of about 6 nm to about 13 nm, and the nanofiber liquid filtration medium has a mean pore size ranging from about 0.01 um to about 0.03 um, a porosity ranging from about 80% to about 95%, a thickness ranging from about 1 um to about 100 um, and a liquid permeability greater than about 10 LMH / psi. The high porosity of the electro-spun mats enable much higher water fluxes, thus reducing the time required to complete virus filtration steps on a fluid stream.

A system for sterilizing or microbially deactivating instruments and devices. The system includes a circulation system for circulating a microbial deactivation fluid through a chamber for containing the instruments and devices. The chamber forms a portion of the circulation system. The system further includes a fluid over-flow / make-up air assembly. The fluid over-flow / make-up air assembly includes a manifold having an inner cavity that is in fluid communication with the circulation system, an overflow port in the manifold, and an overflow valve assembly disposed in the manifold allowing fluid flow from the cavity to the overflow port when a pressure in the cavity exceeds a pressure in the overflow port by a predetermined amount. A filter assembly is attached to the manifold. The filter assembly has a filter valve assembly in communication with the cavity. The filter assembly is operable to allow air through the filter assembly into the cavity when the pressure within the cavity is a predetermined amount less than the pressure within the filter assembly.